Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
PONTE VEDRA, Fla., Oct. 24, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the “Company” or “Cadrenal”), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for